Cephalon And Barr Reach Patent Settlements For Provigil, Actiq
This article was originally published in The Pink Sheet Daily
Executive Summary
Barr could gain up to two months of exclusivity for its Actiq generic.
You may also be interested in...
Nuvigil May Be Further Delayed As FDA Reviews Side Effect Profile
Cephalon plans to submit information to FDA within “the next few weeks.”
Nuvigil May Be Further Delayed As FDA Reviews Side Effect Profile
Cephalon plans to submit information to FDA within “the next few weeks.”
See You In September: Cephalon Anticipates Generic Actiq Ahead Of Fentora Follow-On
Barr reports plans to begin selling a generic version of the pain drug in the second half of September.